What the research found

A study of 861 Scottish adults born in 1936, tracked between ages 70–89, directly compared how well different aging biomarkers predict mortality. The researchers measured epigenetic clocks (particularly GrimAge2), organ-specific protein signatures, physical function tests, brain imaging, and lung capacity—then examined which ones independently predicted death.

GrimAge2, an epigenetic mortality clock, showed the strongest overall association with all-cause mortality. However, four biomarkers emerged with the most independent predictive power when redundancy was minimized: white matter volume, total brain volume, walking speed, and general cognitive function (g). These four accounted for 19% of mortality risk variance; adding 17 other biomarkers only improved prediction by 4%. Among individual proteins, GDF15 (linked to cellular senescence) was strongest after lifestyle adjustment, while a neuropeptide called NPS showed protective association with longevity.

Why it matters for you

If you're tracking biomarkers for longevity, this work suggests that simple, inexpensive measurements may outperform fancy proteomics. Walking speed and cognitive testing are free; brain MRI is not. The finding that organ-specific protein clocks don't correlate well with each other or with physical measures implies that a single "liver age" or "immune age" reading tells you little about your actual mortality risk—a useful reality check against assuming one biomarker captures your overall aging state.

The identification of GDF15 as a mortality predictor may interest those running peptide or supplement protocols aimed at reducing inflammation or senescence; GDF15 appears in blood work and could serve as a trackable marker if you're implementing interventions. Conversely, the neuropeptide NPS association hints at longevity pathways worth investigating, though this is observational data and doesn't explain causation.

Caveats

• Cohort homogeneity: All participants were Scottish, born in the same year, and healthy enough to survive to age 70+—results may not generalize to younger, more diverse, or less healthy populations.
• Cross-sectional snapshot: Measurements were taken at single time points; the study didn't track how changes in biomarkers over time predict mortality, only baseline values.
• Observational only: No interventions tested; cannot infer that improving walking speed or brain volume would reduce mortality, only that they correlate with it.
• Small effect sizes: Four biomarkers together explained only 19% of mortality variance—78% remains unexplained by the measured variables.
• Age-specific: Findings apply to people in their 70s–80s; applicability to younger adults unclear.